Directly acting antivirals for hepatitis C and antiretrovirals: Potential for drug-drug interactions

Current Opinion in HIV and AIDS

Volumn 6, Issue 6, 2011, Pages 514-526

  Seden, Kay ^a,b   Back, David ^b  

^a ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

antiretrovirals; directly acting antivirals; drug interactions; hepatitis C; HIV

Indexed keywords

ABACAVIR; ABT 072; ABT 333; ANA 598; ANTIRETROVIRUS AGENT; ATAZANAVIR; BL 201335; BL 207127; BOCEPREVIR; CYTOCHROME P450 3A4; DANOPREVIR; DARUNAVIR; EFAVIRENZ; FOSAMPRENAVIR; GS 9251; GS 9256; IDX 375; INX 189; ITMN 19; LOPINAVIR; MERICITABINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PEGINTERFERON; PSI 7977; PSI 938; RG 7432; RIBAVIRIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SERINE PROTEINASE INHIBITOR; TEGOBUVIR; TELAPREVIR; TENOFOVIR; TMC 435350; UNCLASSIFIED DRUG; VANIPREVIR;

ANEMIA; ANTIVIRAL THERAPY; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HEPATITIS C; HUMAN; LOW DRUG DOSE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRAL CLEARANCE;

ANTI-HIV AGENTS; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; COINFECTION; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; OLIGOPEPTIDES; PROLINE; PROTEASE INHIBITORS;

EID: 80054908770     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32834b54dc     Document Type: Review

References (58)

1. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29 (Suppl 1):74-81.
2. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5:558-567. (Pubitemid 41196755)
3. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
4. Muir AJ, Hu KQ, Gordon SC, et al. Hepatitis C treatment among racial and ethnic groups in the IDEAL trial. J viral Hepat 2011; 18:e134-e143.
5. Pawlotsky JM, Chevaliez S,McHutchison JG. The hepatitisC virus life cycle as a target for new antiviral therapies. Gastroenterology 2007; 132:1979-1998. (Pubitemid 46695724)
6. Chevaliez S, Pawlotsky JM. HCv genome and life cycle. 2006. 7
7. Seden K, Back D, Khoo S. New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. J Antimicrob Chemother 2010; 65:1079-1085.
8. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage Liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32:492-497. (Pubitemid 32173638)
9. Evans-Jones JG, Cottle LE, Back DJ, et al. Recognition of risk for clinically significant drug interactions among HIv-infected patients receiving antiretroviral therapy. Clin Infect Dis 2010; 50:1419-1421.
10. de Maat MM, de Boer A, Koks CH, et al. Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIv-care. J Clin Pharm Ther 2004; 29:121-130. (Pubitemid 38482476)
11. Bani-Sadr F, Denoeud L, Morand P, et al. Early virologic failure in HIvcoinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role? J Acquir Immune Defic Syndr 2007; 45:123-125. (Pubitemid 46684453)
12. Mira JA, Lopez-Cortes LF, Barreiro P, et al. Efficacy of pegylated interferon plus ribavirin treatment in HIv/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. J Antimicrob Chemother 2008; 62:1365-1373.
13. Mira JA, Lopez-Cortes LF, Merino D, et al. Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIv-HCvcoinfected patients. Antivir Ther 2007; 12:1225-1235.
14. Bani-Sadr F, Carrat F, Pol S, et al. Risk factors for symptomatic mitochondrial toxicity in HIv/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy. J Acquir Immune Defic Syndr 2005; 40:47-52. (Pubitemid 41233204)
15. Rodriguez-Novoa S, Morello J, Gonzalez M, et al. Increase in serum bilirubin in HIv/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin. AIDS 2008; 22:2535-2537.
16. Torti C, Lapadula G, Antinori A, et al. Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER cohorts. Infection 2009; 37:244-249.
17. Tozzi v. Pharmacogenetics of antiretrovirals. Antiviral Res 2010; 85:190-200.
18. Laguno M, Blanch J, Murillas J, et al. Depressive symptoms after initiation of interferon therapy in human immunodeficiency virus-infected patients with chronic hepatitis C. Antivir Ther 2004; 9:905-909. (Pubitemid 40040264)
19. Barski OA, Tipparaju SM, Bhatnagar A. The aldo-keto reductase superfamily and its role in drug metabolism and detoxification. Drug Metab Rev 2008; 40:553-624.
20. victrelis1 (Boceprevir) US Prescribing Information, FDA. http://www.merck. com/product/usa/pi-circulars/v/victrelis/victrelis-pi.pdf. [Accessed 30 June 2011]
21. Kasserra C, Hughes, E, Treitel M, et al. Clinical pharmacology of BOC: metabolism, excretion and drug-drug interactions. In: Abstracts of the 18th Conference on Retroviruses and Opportunistic Infections; 27 February to 2 March 2011; Boston, USA; abstract 118.
22. van Heeswijk Rv, Boogaerts A,Get al. Pharmacokinetic interactions between ARv agents and the investigational HCv protease inhibitor TvR in healthy volunteers. In: Abstracts of the 18th conference on Retroviruses and Opportunistic Infections; 27 February to 2 March 2011; Boston, USA; abstract 119.
23. Garg vL, McNair X, L et al. Low dose RTv and the pharmacokinetics of the investigational HCv protease inhibitor TvR in healthy volunteers. In: Abstracts of the 18th Conference on Retroviruses and Opportunistic Infections; 27 February to 2 March 2011; Boston, USA; abstract 629.
24. Garg vL, McNair X, L et al. The effect of low dose ritonavir on the pharmacokinetics of the HCv protease inhibitor telaprevir in healthy volunteers. In: Abstracts of the 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy; 22-23 June 2011; Cambridge, MA, USA; abstract PK15.
25. Garg v, Chandorkar G, Yang Y, et al. The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir. In: Abstracts of the 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy; 22-23 June 2011; Cambridge, MA, USA; abstract PK13.
26. Incivek1 (Telaprevir) US Prescribing Information, FDA http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/201917lbl.pdf. [Accessed 30 June 2011]
27. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCv genotype 1 infection. N Engl J Med 2011; 364:1195-1206.
28. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCv genotype 1 infection. N Engl J Med 2011; 364:1207-1217.
29. Schering-Plough Ltd. Rebetolw summary of product characteristics. http:// emc.medicines.org.uk. [Accessed 29 May 2009]
30. Luo XvH, Alves R, K et al. The effect of telaprevir on the pharmacokinetics of alprazolam and zolpidem in healthy volunteers. In: Abstracts of the 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy; 22-23 June 2011; Cambridge, MA, USA; abstract PK11.
31. van Heeswijk R, Boogaerts G, Garg v, et al. The pharmacokinetic (PK) interaction between escitalopram and the investigational HCv protease inhibitor telaprevir. In: Abstracts of the 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy; 23-24 June 2010; Boston, MA, USA; abstract 12.
32. Lee J, van Heeswijk R, Alves K, et al. The pharmacokinetic interaction between amlodipine or atorvastatin and the HCv protease inhibitor telaprevir. In: Abstracts of the 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy; 22-23 June 2011; Cambridge, MA, USA; abstract PK14.
33. Garg vC, Smith G, F et al. The effect of telaprevir on the pharmacokinetics of midazolam and digoxin. In: Abstracts of the 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy; 22-23 June 2011; Cambridge, MA, USA; abstract PK12.
34. van Heeswijk R, Boogaerts G, De Backer K, et al. The pharmakokinetic (PK) interaction between esomeprazole and the investigational HCv protease inhibitor telaprevir. In: Abstracts of the 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy; 23-24 June 2010; Boston, MA, USA; abstract 11.
35. Garg v, van Heeswijk R, Lee J, et al. Significant effect of the HCv protease inhibitor telaprevir on cyclosporine and tacrolimus pharmacokinetics. In: Abstracts of the 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy; 22-23 June 2011; Cambridge, MA, USA; abstract PK16.
36. Garg vY, Smith Y, F et al. The pharmacokinetic interaction between an oral contraceptive containing ethinyl estradiol and norethindrone and telaprevir. In: Abstracts of the 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy; 22-23 June 2011; Cambridge, MA, USA; abstract PK17.
37. van Heeswijk R, vandevoorde A, verboven P, et al. The pharmacokinetic interaction between methadone and the investigational HCv protease inhibitor telaprevir [abstract 1244]. J Hepatol 2011; 54 (Suppl 1):S491.
38. Sulkowski M, Dieterich, D, Sherman, K, et al. New HIv and HCv antiviral agents, prevention, and ARv strategies. In: Abstracts of the 18th Conference on Retroviruses and Opportunistic Infections; 27 February to 2 March 2011; Boston, USA; abstract 146LB.
39. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCv genotype 1 infection. N Engl J Med 2009; 360:1827-1838.
40. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCv infection. N Engl J Med 2009; 360:1839-1850.
41. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCv infection. N Engl J Med 2011; 364:2417-2428.
42. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-2416.
43. Gane EJ, Rouzier R, Stedman C, et al. Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN alpha-2a/RBv in hepatitis C patients. J Hepatol 2011. [Epub ahead of print]
44. Mathias AA, German P, Murray BP, et al. Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIv activity. Clin Pharmacol Ther 2010; 87:322-329.
45. Zeuzem S, Foster G, Fried M, et al. The ASPIRE trial: TMC435 in treatmentexperienced patients with genotype-1 HCv infection who have failed previous PEGIFN/RBv treatment [abstract 1376]. J Hepatol 2011; 54 (Suppl 1):S546.
46. Sulkowski M, Bourliere M, Bronowicki J-P, et al. SILEN-C2: sustained virological response (SvR) and safety of BI201335 combined with peginterferon alfa-2a and ribavirin (P/R) in chronic HCv genotype-1 patients with nonresponse to P/R [abstract 66]. J Hepatol 2011; 54 (Suppl 1):S30.
47. Corsa A, Robinson M, Yang H, et al. Preclinical properties of the novel HCv NSvprotease inhibitor GS-9451 [abstract 778]. J Hepatol 2011; 54 (Suppl 1): S313.
48. Yang H, Yang C, Wang G, et al. Preclinical characterisation of the novel HCv NSvprotease inhibitor GS-9256 [abstract 779]. J Hepatol 2011; 54 (Suppl 1): S313.
49. Tong LM, Roy J, A et al. In vitro studies on the potential for the hepatitis C virus protease inhibitors GS-9256 and GS-9451 to affect bilirubin elimination [abstract 1232]. J Hepatol 2011; 54 (Suppl 1):S487.
50. Sane R, Podila L, Mathur A, et al. mechanisms of isolated unconjugated hyperbilirubinaemia induced by the HCv NS3/4A protease inhibitor BI201335 [abstract 1236]. J Hepatol 2011; 54 (Suppl 1):S488.
51. Dumas E, Lawal A, Menon R, et al. Pharmacokinetics, safety and tolerability of the HCv NS5A inhibitor ABT-267 following single and multiple doses in healthy adult volunteers [abstract 1204]. J Hepatol 2011; 54 (Suppl 1): S475.
52. Haznedar JOv, Kulkarni C,Ret al. Lack ofRG7128effect on cardiac conduction in a thorough QT study [abstract 1246]. J Hepatol 2011; 54 (Suppl 1):S.492.
53. Yang CWY, Wieman L. Preclinical pharmacokinetic characterisation of GS- 9190, a novel nonnucleoside HCv NS5B polymerase inhibitor. [abstract 1398]. Hepatology 2007; 46 (Suppl 1):860A.
54. Flisiak R, Feinman Sv, Jablkowski M, et al. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatmentnaive hepatitis C patients. Hepatology 2009; 49:1460-1468.
55. Flisiak R, Pawlotsky J-M, Crabbe M, et al. Once daily alisporivir (Deb025) plus PEG IFN Alfa 2a/ribavirin results in superior sustained virological response (SvR24) in chronic hepatitis C genotype 1 treatment naive patients [abstract 4]. J Hepatol 2011; 54 (Suppl 1):S2
56. Crabbe R, vuagniaux G, Dumont JM, et al. An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C. Expert Opin Investig Drugs 2009; 18:211-220.
57. Lawitz E, Godofsky E, Rouzier R, et al. Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCv-infected patients receiving 14 days of therapy. Antiviral Res 2011; 89:238-245.
58. Lankisch TO, Behrens G, Ehmer U, et al. Gilbert's syndrome and hyperbilirubinemia in protease inhibitor therapy: an extended haplotype of genetic variants increases risk in indinavir treatment. J Hepatol 2009; 50:1010-1018.